MONDAY, April 28, 2025 -- A ready-made version of a cutting-edge cancer immunotherapy can effectively defeat

2025年4月28日，星期一——一种现成的尖端癌症免疫疗法可以有效战胜

blood cancers

血液癌症

, a new study says.

，一项新的研究说。

Researchers have prepared an off-the-shelf version of CAR immune cell treatment that can be administered more easily to patients with blood cancers.

研究人员已经制备出一种可随时使用的CAR免疫细胞疗法版本，可以更方便地应用于血液癌症患者。

The new treatment, which uses a type of immune cell called natural killer cells, promoted complete remission in several patients with acute myeloid leukemia (AML), researchers said yesterday in a presentation at an American Association for Cancer Research’s (AACR) meeting in Chicago.

研究人员昨日在芝加哥举行的美国癌症研究协会 (AACR) 会议上发表演讲时表示，这种使用一种名为自然杀伤细胞的免疫细胞的新疗法，使多名急性髓系白血病 (AML) 患者达到了完全缓解。

“The deep and durable responses observed in patients for whom we have follow-up data are impressive,” lead investigator

“我们有随访数据的患者中观察到的深度且持久的反应令人印象深刻，”首席研究员表示。

Dr. Stephen Stricklan Jr.

小斯蒂芬·斯特里克兰博士

, director of leukemia research at the Sarah Cannon Research Institute in Nashville, Tenn., said in a news release. “We are hopeful this can be a new type of treatment for AML patients where the unmet medical need is extremely high.”

田纳西州纳什维尔市莎拉·坎农研究所的白血病研究主任在新闻发布会上说：“我们希望这可以成为急性髓系白血病患者的一种新治疗方法，因为这种疾病尚未满足的医疗需求非常高。”

CAR T-cell therapy has been making waves as a means of fighting blood cancers. Doctors take a person’s own immune T cells, use genetic engineering to teach the cells how to detect and kill that patient’s specific cancer, then infuse the cells back into the person.

CAR T细胞疗法作为一种对抗血癌的手段，已经引起了轰动。医生提取患者自身的免疫T细胞，通过基因工程教会这些细胞如何识别并杀死该患者特定的癌症，然后将这些细胞输回患者体内。

However, the process takes laboratory time that patients with fast-progressing leukemia might not have, researchers said. In addition, patients with AML often have dysfunctional T-cells, which can make it tough to engineer them properly.

然而，研究人员表示，这个过程需要实验室时间，而病情进展迅速的白血病患者可能无法等待。此外，急性髓系白血病患者通常存在功能异常的T细胞，这可能使正确改造它们变得困难。

The new treatment is called CAR NK-cell therapy because it relies on natural killer cells, researchers said.

研究人员称，这种新疗法被称为CAR NK细胞疗法，因为它依赖于自然杀伤细胞。

Like T cells, NK cells can be engineered to target cancer cells, but they can be crafted from the blood of healthy donors and stored for future use – essentially making them shelf-stored treatments that can be given to patients quickly, rather than personalized therapies that require genetic manipulation in a lab..

像T细胞一样，NK细胞也可以被改造来靶向癌细胞，但它们可以由健康捐赠者的血液制成并储存以备将来使用——这使其本质上成为可快速给予患者的现成治疗手段，而非需要在实验室中进行基因操作的个性化疗法。

For the new study, researchers tested a CAR NK-cell therapy formulation called SENTI-202.

对于这项新研究，研究人员测试了一种名为 SENTI-202 的 CAR NK 细胞疗法制剂。

The NK cells in SENTI-202 have been built to identify two different target proteins found on leukemia cells, helping them to find and kill cancer cells that carry either of the two markers, researchers said.

研究人员称，SENTI-202中的NK细胞被设计为可识别白血病细胞上的两种不同靶蛋白，帮助它们找到并杀死携带这两种标记物的癌细胞。

The NK cells also carry an additional receptor meant to prevent them from killing healthy, non-cancerous cells that carry either of the target proteins, researchers said. This “logic-gating” behavior causes the immune cells to ignore any cells that express a protein found on healthy stem cells.

研究人员称，NK细胞还携带一个额外的受体，旨在防止它们杀死携带任一目标蛋白的健康、非癌细胞。这种“逻辑门控”行为使免疫细胞忽略表达在健康干细胞上发现的蛋白质的任何细胞。

The AACR presentation focused on the first nine patients to receive SENTI-202 after their leukemia either failed to respond to other treatments or came back.

AACR 的报告重点关注了前九名在接受 SENTI-202 治疗后，其白血病对其他治疗无反应或复发的患者。

The patients received chemo to deplete their immune systems, and then were infused with SENTI-202.

患者接受了化疗以削弱其免疫系统，随后被注入了SENTI-202。

Four of the patients experienced a complete remission, with no measurable evidence of any cancer cells left in their blood, researchers said. A fifth patient experienced a substantial response that equates a “leukemia-free state.”

研究人员表示，其中四名患者经历了完全缓解，血液中已没有任何可测量的癌细胞证据。第五名患者出现了显著的反应，相当于“无白血病状态”。

While the results are preliminary, Strickland said they are encouraging for the development of generalized immune therapies that are easier to make and administer.

虽然结果是初步的，但斯特里克兰说，这对于开发更容易生产和使用的通用免疫疗法而言是令人鼓舞的。

“There are very few ‘clean’ cancer targets that are only expressed on cancer cells but not on healthy cells,” Strickland said. “The logic-gating technology potentially solves this issue by recognizing one or more cancer targets to trigger deeper cancer killing while recognizing healthy cells to prevent them from being affected.”.

“很少有‘干净’的癌症靶点仅在癌细胞上表达而不在健康细胞上表达，”斯特里克兰说。“逻辑门控技术通过识别一个或多个癌症靶点来触发更深层次的癌细胞杀伤，同时识别健康细胞以防止它们受到影响，从而可能解决这个问题。”

These were very preliminary trial results, researchers said, and more patients continue to be enrolled in studies of the safety and effectiveness of SENTI-202.

研究人员表示，这些是非常初步的试验结果，更多患者将继续参与 SENTI-202 的安全性和有效性研究。

Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.

在医学会议上发表的研究结果，在发表于经过同行评审的期刊之前，应被视为初步结果。

Whatever your topic of interest,

无论你感兴趣的话题是什么，

subscribe to our newsletters

订阅我们的新闻通讯

to get the best of Drugs.com in your inbox.

获取 Drugs.com 的最佳资讯到您的收件箱。